



**FOR IMMEDIATE RELEASE**

**GattaCo Signs Supply Agreement with Gravidas for Use of GattaCo's Self-Collected Plasma Separation Device with Gravidas' Outpatient Preeclampsia Diagnostic Test**

Murietta, CA- July 25, 2023- GattaCo, an innovator in blood collection and testing technology, announces the signing of a supply agreement for its self-collected plasma separation platform.

“GattaCo’s cost-effective technology enables diagnostics companies and laboratories to provide their existing test-menu to consumers anywhere, driving adoption by patients, consumers, health systems, and governments on a global scale” explained Mahmoud Zubaidi, GattaCo’s recently appointed CEO.

Gravidas is developing a diagnostic or prognostic tests to determine levels of preeclampsia specific biomarker in blood samples to assess risk of development or progression of the disease in pregnant women, where such tests are used in an outpatient setting such as emergency departments, healthcare clinics or point-of-care facilities.

70% of all diagnostic tests are blood tests, which are at risk for hemolysis, the bursting of red blood cells if not removed promptly from the sample. Hemolysis leads to 60% of all rejected samples and can result in misdiagnosis and incorrect treatment. GattaCo’s technology separates blood plasma before hemolysis occurs, thereby supporting decentralized clinical trials, direct-to-consumer, and point of care applications where lab quality samples and remote patient access are required.

“GattaCo’s unique technology results in high quality and metered plasma that can be obtained anywhere in under three minutes, removing the phlebotomist, cold-chain transport, and centrifuge infrastructure that is otherwise required. It eliminates the challenges and errors associated with liquid blood collection devices, dried blood spots, and high costs of mobile phlebotomy, “ said Mr. Zubaidi.

**About GattaCo**

GattaCo, an innovator in at-home blood collection and testing, is revolutionizing the blood testing industry with the first at-home lab quality blood plasma collection kit thereby eliminating cumbersome processing steps while increasing patient access. GattaCo’s technology supports decentralized clinical trials, direct-to-consumer, and point of care applications. For more information, please visit, [GattaCo.com](http://GattaCo.com)

**Contact:**

[info@gattaco.com](mailto:info@gattaco.com)